Standout Papers

Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial 2024 202639
  1. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial (2024)
    Howard A. Burris, Takuji Okusaka et al. The Lancet Oncology

Immediate Impact

66 standout
Sub-graph 1 of 22

Citing Papers

Pancreatic cancer
2025 Standout
Advanced disease therapeutics using engineered living drug delivery systems
2025 Standout
2 intermediate papers

Works of Nikunj Patel being referenced

Considerations for development of an evidence dossier to support the use of mobile sensor technology for clinical outcome assessments in clinical trials
2020
Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib
2019

Author Peers

Author Last Decade Papers Cites
Nikunj Patel 202 192 93 156 66 780
Pei Zhang 50 75 30 30 80 891
Zouina Sarfraz 44 83 76 26 125 863
Azza Sarfraz 36 78 77 26 103 819
Lei Du 124 17 101 18 60 663
Giovanni De Luca 229 36 59 44 73 675
Yu-Chia Chang 69 136 185 21 57 855
Daniel Faber 33 26 45 28 58 961
Lionel Védrine 155 175 176 59 80 765
Suhong Luo 14 296 123 207 62 875
Jinchao Wang 268 12 38 11 64 761

All Works

Loading papers...

Rankless by CCL
2026